We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

HbA1c Assessed in Diabetics Awaiting Liver Transplantation

By LabMedica International staff writers
Posted on 31 Dec 2018
Print article
Image: Glycated hemoglobin (HbA1c) as an indicator of diabetes (Photo courtesy of Diabetes.co.uk).
Image: Glycated hemoglobin (HbA1c) as an indicator of diabetes (Photo courtesy of Diabetes.co.uk).
A glycated hemoglobin (HbA1c) test measures the amount of blood sugar (glucose) attached to hemoglobin. An HbA1c test shows what the average amount of glucose attached to hemoglobin has been over the past three months. It's a three-month average because that's typically how long a red blood cell lives.

Diabetes is a leading cause of liver disease, with cirrhosis responsible for a considerable number of deaths in people with diabetes. The relationship between HbA1c and glucose in people with co-existing liver disease and diabetes awaiting transplant, and in those with diabetes but no liver disease has been investigated.

Scientists collaborating with the University of Birmingham (Birmingham, UK) collected HbA1c and random plasma glucose data for 125 people with diabetes without liver disease and for 29 people awaiting liver transplant with diabetes and cirrhosis. The median (interquartile range) Model for End Stage Liver Disease score for the study cohort was calculated as 12 (9-17; normal is less than 6). In those with cirrhosis, this was caused by non-alcoholic fatty liver disease, hepatitis C, alcoholic liver disease, hereditary hemochromatosis, polycystic liver/kidneys, cryptogenic/non-cirrhotic portal hypertension and α-1-antitrypsin-related disease.

The team found that the median (interquartile range) HbA1c concentrations were 41 (32-56) mmol/mol [5.9 (5.1-7.3)]% versus 61 (52-70) mmol/mol [7.7 (6.9-8.6)%], respectively, in the diabetes with cirrhosis group versus the diabetes without cirrhosis group and the glucose concentrations were 8.4 (7.0-11.2) mmol/L versus 7.3 (5.2-11.5) mmol/L. HbA1c concentration was depressed by 20 mmol/mol (1.8%) in 28 participants with cirrhosis, but elevated by 28 mmol/mol (2.6%) in the participant with α-1-antitrypsin disorder.

Those with cirrhosis and depressed HbA1c concentrations had fewer larger erythrocytes, and higher red cell distribution width and reticulocyte count. This was reflected in the positive association of glucose with mean cell volume and hemoglobin level and the negative association for HbA1c concentration in the diabetes group. The authors concluded that HbA1c is not an appropriate test for blood glucose in people with cirrhosis and diabetes awaiting transplant as it reflects altered erythrocyte presentation. The study was published on November 26, 2018, in the journal Diabetic Medicine.

Related Links:
University of Birmingham

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.